FDA approve ansuvimab-zykl for Ebola

The FDA have approved this monoclonal antibody isolated from a human survivor of the 1995 Ebola outbreak on the basis of data from the PALM RCT. A market authorisation application has not yet been forwarded for the EMA to review.

Source:

PharmaTimes